Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents

Nogic, Jason; McCormick, Liam; Francis, Rohin; Nerlekar, Nitesh; Jaworski, Catherine; West, Nick E.J.; Brown, Adam

doi:10.1016/j.jjcc.2017.12.007

Cited by 30 publications

(22 citation statements)

References 95 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…S.p.A., Saluggia, Italy) are used in clinical practice. The Yinyi and Yukon Choice stents are microporous, while the Cre8 stent is macroporous with a textured rough surface . The Nano+™ is a PF stent with a nano‐sized‐pore surface, which has a higher uniform distribution on the adluminal stent surface than microporous, microporous, or textured rough surface stents …”

Section: Discussionmentioning

confidence: 99%

“…Univariate analyses (Table S2) 95% CI: 1.31-8.04; p = .01), chronic total occlusion (CTO) (HR: 2.52; 95% CI: 1.55-4.09; p < .01), and long lesions (>40 mm) (HR: 1.81; 95% CI: 1.06-3.11; p = .03) were associated with an increased risk of 1-year TLF. In multivariate analysis (Table S2) 17 The Nano+™ is a PF stent with a nano-sized-pore surface, which has a higher uniform distribution on the adluminal stent surface than microporous, microporous, or textured rough surface stents. 9 In randomized studies of selected patients, the Yukon Choice stent 18 and BioFreedom Biolimus A9-Coated stent 19 were noninferior to the new generation of durable polymer DESs and bare-metal stent with respect to the 12-month clinical outcomes, respectively.…”

Section: Predictors Of Tlf At the One-year Follow-upmentioning

confidence: 99%

See 1 more Smart Citation

One‐year clinical results of the NANO registry: A multicenter, prospective all‐comers registry study in patients receiving implantation of a polymer‐free sirolimus‐eluting stent

Liu

Zhang

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives We aimed to evaluate the safety and efficacy of Nano+™ (Lepu Medical, Beijing, China) stent implantation in all‐comer patients at the 1‐year follow‐up. Background The Nano+™ stent is a novel polymer‐free sirolimus‐eluting stent polymer that employs nanoporous stent surface technology to control drug‐delivery. The Nano+™ stent is one of the most widely used drug‐eluting stent (DES) in China. Methods A total of 2,481 consecutive patients were included in the multicenter and prospective NANO registry. In this study, the primary endpoint was target lesion failure (TLF) at 1‐year follow‐up, defined as a composite of cardiac death, target vessel nonfatal myocardial infarction (TV‐MI), and clinically driven target lesion revascularization (TLR). The safety endpoint was the occurrence of definite or probable stent thrombosis (ST). Results Up to 40.2% of patients presented with acute myocardial infarction (AMI). A total of 63.9% of the 2,904 lesions were American College of Cardiology/American Heart Association (ACC/AHA) type B2 or C lesions. One‐year follow‐up data were available for 98.4% of patients. The 1‐year rate of TLF was 3.1% with rates of 1.3, 1.8, and 0.4% for clinically driven TLR, cardiac death, and TV‐MI, respectively. ST occurred in 0.4% of patients. Diabetes mellitus, AMI, left ventricular ejection fraction <40% and long lesions (>40 mm) were independent predictors of 1‐year TLF. Conclusions The 1‐year clinical outcomes were excellent for Nano+™ polymer‐free SES implantation in an all‐comer patient population. Follow‐up will be extended up to 5 years, to further elucidate the potential long‐term clinical benefits. Clinical Trial Registration URL: https://www.clinicaltrials.gov/. Unique identifier: NCT02929030.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Predictors Of Tlf At the One-year Follow-upmentioning

confidence: 99%

One‐year clinical results of the NANO registry: A multicenter, prospective all‐comers registry study in patients receiving implantation of a polymer‐free sirolimus‐eluting stent

Liu

Zhang

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Recently, third-generation stents covered with fully biodegradable polymers such as PLGA and PLA have appeared on the market. [ 71 , 72 ]. One example is the everolimus-eluting stent, which consists of a platinum-chromium (Pt-Cr) platform coated with a biodegradable PLGA copolymer.…”

Section: Drug-eluting Stents (Des)mentioning

confidence: 99%

Drug-Eluting Stents and Balloons—Materials, Structure Designs, and Coating Techniques: A Review

Rykowska

Nowak

Nowak³

2020

Molecules

View full text Add to dashboard Cite

Controlled drug delivery is a matter of interest to numerous scientists from various domains, as well as an essential issue for society as a whole. In the treatment of many diseases, it is crucial to control the dosing of a drug for a long time and thus maintain its optimal concentration in the tissue. Heart diseases are particularly important in this aspect. One such disease is an obstructive arterial disease affecting millions of people around the world. In recent years, stents and balloon catheters have reached a significant position in the treatment of this condition. Balloon catheters are also successfully used to manage tear ducts, paranasal sinuses, or salivary glands disorders. Modern technology is continually striving to improve the results of previous generations of stents and balloon catheters by refining their design, structure, and constituent materials. These advances result in the development of both successive models of drug-eluting stents (DES) and drug-eluting balloons (DEB). This paper presents milestones in the development of DES and DEB, which are a significant option in the treatment of coronary artery diseases. This report reviews the works related to achievements in construction designs and materials, as well as preparation technologies, of DES and DEB. Special attention was paid to the polymeric biodegradable materials used in the production of the above-mentioned devices. Information was also collected on the various methods of producing drug release coatings and their effectiveness in releasing the active substance.

show abstract

“…Além dessa, outras limitações são encontradas com o uso desses dispositivos, estudos mostram que cerca de 1 em cada 10 pacientes que receberam dispositivos de primeira geração, necessita de uma repetição da intervenção em um período de cinco anos devido os processos de reestenose recorrentes, demonstrando uma deficiência do stent a longo prazo, e consequentemente elevando as inúmeras preocupações relacionadas a segurança do dispositivo (Nogic et al, 2018).…”

Section: Stent Farmacológico De Primeira Geraçãounclassified

Gerações de stents no tratamento da cardiopatia isquêmica

Ferreira¹,

Gusmão²,

Duarte³

et al. 2020

RSD

View full text Add to dashboard Cite

A Doença Arterial Coronariana predispõe o desenvolvimento de doenças isquêmicas cardíacas, sendo uma das principais causas de morbimortalidade em todo mundo. As intervenções coronarianas percutâneas revascularizam o miocárdio por meio da implantação de stents a fim de restabelecer o fluxo sanguíneo nas artérias afetadas. Devido à alta no uso desses dispositivos nos procedimentos percutâneos, bem como as limitações atualmente encontradas, como trombose de stent, reestenose e eventos cardíacos adversos, o objetivo do presente estudo foi analisar as publicações que tratam das diversas gerações de stents no tratamento da doença arterial coronariana, através de uma revisão literária, com busca nas bases Scielo, Pubmed e Sciencedirect. Os stents farmacológicos surgiram como uma alternativa mais segura e eficaz que os stents convencionais, reduzindo episódios de reestenose e eventos cardíacos adversos maiores. No entanto, um maior risco de trombose ligada ao seu uso foi observado. Assim, por meio de um aperfeiçoamento no design, bem como dos materiais utilizados na sua fabricação, diversas gerações de stents farmacológicos foram desenvolvidas, ampliando o acervo terapêutico. Apesar disso, novos estudos ainda são necessários para comprovar sua segurança a longo prazo.

show abstract

Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents

Cited by 30 publications

References 95 publications

One‐year clinical results of the NANO registry: A multicenter, prospective all‐comers registry study in patients receiving implantation of a polymer‐free sirolimus‐eluting stent

One‐year clinical results of the NANO registry: A multicenter, prospective all‐comers registry study in patients receiving implantation of a polymer‐free sirolimus‐eluting stent

Drug-Eluting Stents and Balloons—Materials, Structure Designs, and Coating Techniques: A Review

Gerações de stents no tratamento da cardiopatia isquêmica

Contact Info

Product

Resources

About